Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Yu. Kulikov
Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma
Pulmonologiya
Pulmonary
Respiratory Medicine
Related publications
Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma
Prescriber
Pharmacology
Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
Prs54 - Cost-Effectiveness Analysis of Reslizumab for Patients With Severe Eosinophilic Asthma Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting B2-Agonists in South Korea
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Severe Eosinophilic Asthma: A Roadmap to Consensus
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Benralizumab for the Treatment of Severe Eosinophilic Asthma
Prescriber
Pharmacology
A High Proportion of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (Wks) of Treatment
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Pharmacy Reimbursement and Pharmacoeconomic Aspects of Therapy of Bronchial Asthma
Pharmacoeconomics: theory and practice
Pharmacoeconomic Analysis of Using Biological Agents for Uncontrolled Moderate-To-Severe Atopic Asthma in the Russian Federation
FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
